Cytokinetics announces additional results from cosmic-hf presented at acc.17 nasdaq_cytk

SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) — Cytokinetics, Inc. Blood plasma concentration (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by Tor Biering-Sorensen, MD, PhD, Postdoctoral Research Fellow, Division of Cardiology, Brigham & Women’s Hospital and Harvard Medical School, in a Poster Session at the American College of Cardiology’s 66 th Annual Scientific Session (ACC.17) in Washington, D.C. Chief component of blood plasma The results presented showed that omecamtiv mecarbil improved myocardial deformation, a marker of myocardial function that has been related to outcomes. Blood plasma density Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.

“These results provide the first, direct echocardiographic evidence in humans that increases in the contractility of cardiac muscle underlie the improvements in overall cardiac function observed in COSMIC-HF,” said Fady I. Blood plasma without the clotting factors is called Malik, MD, PhD, Cytokinetics’ Executive Vice President, Research and Development.

The expansion phase of COSMIC-HF evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction. How much of the blood is plasma Patients were randomized 1:1:1 to receive either placebo or treatment with omecamtiv mecarbil dosed as 25 mg twice daily or 25 mg twice daily with dose escalation to 50 mg twice daily, depending on a plasma concentration of omecamtiv mecarbil after two weeks of treatment. What color is blood plasma The study met its primary pharmacokinetic objective and showed statistically significant improvements in all pre-specified secondary measures of cardiac function in the treatment group receiving pharmacokinetic-based (PK) dose titration.


In this analysis, measures of left ventricular (LV) myocardial deformation, including global circumferential strain (GCS) and mean global longitudinal strain (GLS), were compared at baseline and at 20 weeks of treatment in the placebo group, the 25 mg twice daily group, and the PK-guided dose titration group. Water in blood plasma At 20 weeks, both mean GLS and GCS improved in the 25 mg twice daily group (p=0.014, p=0.001, respectively), and showed a trend towards improvement in the PK-guided dose titration group (p=0.06, p=0.13, respectively). Is plasma in blood These results further support that omecamtiv mecarbil directly improves myocardial contractile function.

Heart failure is a grievous condition that affects more than 23 million people worldwide, about half of whom have reduced left ventricular function. Plasma blood glucose It is the leading cause of hospitalization and readmission in people age 65 and older. Blood plasma hair treatment Despite broad use of standard treatments and advances in care, the prognosis for patients with heart failure is poor. Blood plasma osmolarity An estimated one in five people over the age of 40 are at risk of developing heart failure, and approximately 50 percent of people diagnosed with heart failure will die within five years of initial hospitalization.

Omecamtiv mecarbil is a novel cardiac myosin activator. Blood plasma donation risks Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Sell blood plasma nyc Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Blood plasma centrifuge Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes.

Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Blood test plasma Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics’ specified development and commercialization rights. Blood plasma disorders Amgen has also entered an alliance with Servier for exclusive commercialization rights in Europe as well as the Commonwealth of Independent States, including Russia. Giving blood plasma for money Servier contributes funding for development and provides strategic support to the program.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Blood plasma products As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Where can i sell blood plasma Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal troponin activator (FSTA). Blood plasma contents Tirasemtiv is the subject of VITALITY-ALS, an international Phase 3 clinical trial in patients with ALS. Low plasma levels in blood Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Plasma serum blood Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. Cytokinetics is preparing for the potential commercialization of tirasemtiv in North America and Europe and has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. Cytokinetics is collaborating with Astellas to develop CK-2127107, a next-generation fast skeletal muscle activator. CK-2127107 is the subject of two ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease. Blood bank plasma Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator. Blood cells plasma Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Plasma and red blood cells Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Serum plasma blood Licenses held by Amgen and Astellas are subject to Cytokinetics’ specified co-development and co-commercialization rights. Blood and plasma center For additional information about Cytokinetics, visit http://www.cytokinetics.com/.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Get paid for blood plasma Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Donate blood plasma for cash Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including the design, results, significance and utility of COSMIC-HF clinical trial results and the potential for success and timing for the progression of omecamtiv mecarbil; and the properties and potential benefits of Cytokinetics’ drug candidates. Donate blood and plasma for money Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Amgen’s decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Buy blood plasma Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. Proteins found in blood plasma For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission. Centrifuge blood plasma Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Plasma extraction from blood Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Substances in blood plasma Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Plasma blood type Contact:

GlobeNewswire, a Nasdaq company, is one of the world’s largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Leave a Reply

Your email address will not be published. Required fields are marked *